Although immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, advantages for advanced NSCLC, in terms of OS, have been reported for EGFR wild-type tumors, but not for EGFR-mutated lung tumors [253]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.